Table 6

Studies investigating correlation of abnormal p53 expression by immunohistochemistry and cancer risk in Barrett's oesophagus

StudyFindingSample sizeEDRN stageGrade of evidence
Weston et al 2001359Kaplan–Meier curves differed significantly between p53-positive and -negative patients for outcome defined as progression of LGDProgressors n=5, non-progressors n=43Prospective phase 4IIa
Murray et al 2006196OAC/HGD end point: OR 8.42 (95% CI 2.37 to 30.0)Progressors n=35, controls n=175Phase 3: retrospectiveIIa
SIkkema et al 2009198HR 6.5 (95% CI 2.5 to 17.1) Remained a risk factor on multivariable analysisProgressors n=27, non-progressors n=27Prospective phase 4IIa
Younes et al 1997370Progression from LGD to HGD/OAC, p=0.0108. p53 accumulation has a sensitivity of 100%, specificity of 93%, and a predictive value of a positive test of 0.56Progressors n=5, non-progressors n=25Phase 3: retrospectiveIIa
Skacel et al 2002130Progression from LGD to HGD/OAC. A correlation with clinical progression was seen, p=0.017 (88% sensitivity and 75% specificity for progression)Progressors n=8, non-progressors n=8Phase 3: retrospectiveIIa
Bani-Hani 2000197OR=2.99 (95% CI=0.57 to 15.76; p=0.197).Nested case–control (unmatched), n=12 casesPhase 3: retrospectiveIIa
Kastelein 2012131RR=6.2 (95% CI=3.6 to 10.9)Progressors n=49,
non-progressors n=586
Phase 3: retrospectiveIIa
  • HGD, high-grade dysplasia; HR, hazard ratio; LGD, low-grade dysplasia; OAC, oesophageal adenocarcinoma; OR, odds ratio.